Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice.

ABSTRACT: Loss of bone and muscle mass are two major clinical complications among the growing list of chronic diseases that primarily affect elderly individuals. Persistent low-grade inflammation, one of the major drivers of aging, is also associated with both bone and muscle dysfunction in aging. Particularly, chronic activation of the receptor for advanced glycation end products (RAGE) and elevated levels of its ligands high mobility group box 1 (HMGB1), AGEs, S100 proteins and Aβ fibrils have been linked to bone and muscle loss in various pathologies. Further, genetic or pharmacologic RAGE inhibition has been shown to preserve both bone and muscle mass. However, whether short-term pharmacologic RAGE inhibition can prevent early bone and muscle loss in aging is unknown. To address this question, w

SUBMITTER: Davis HM 

PROVIDER: S-EPMC6543548 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature